Novel immunohistochemical markers in the diagnosis of nonglial tumors of nervous system

Advances in Anatomic Pathology

Volumn 17, Issue 2, 2010, Pages 150-153

  Takei, Hidehiro ^a   Powell, Suzanne Z ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Immunohistochemistry; Nervous system; Nonglial tumors

Indexed keywords

AQUAPORIN 1; BETA CATENIN; INHIBIN A;

AUTOSOMAL DOMINANT DISORDER; CHORDOMA; CLEAR CELL CARCINOMA; CRANIOPHARYNGIOMA; GENE EXPRESSION; GERM LINE; HEMANGIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; NEURILEMOMA; PRIORITY JOURNAL; REVIEW; VON HIPPEL LINDAU DISEASE;

AQUAPORIN 1; BETA CATENIN; BRAIN NEOPLASMS; CHORDOMA; CHROMOSOMAL PROTEINS, NON-HISTONE; CRANIOPHARYNGIOMA; DNA-BINDING PROTEINS; FETAL PROTEINS; HEMANGIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBINS; NEURILEMMOMA; T-BOX DOMAIN PROTEINS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77649144624     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181cfb7ae     Document Type: Review

References (35)

1. Hamazaki S, Nakashima H, Matsumoto K, et al. Metastasis of renal cell carcinoma to central nervous system hemangioblastoma in two patients with von Hippel-Lindau disease. Pathol Int. 2001;51:948-953.
2. Mottolese C, Stan H, Giordano F, et al. Metastasis of clear cell renal cell carcinoma to cerebellar hemangioblastoma in von Hippel Lindau disease: rare or not investigated? Acta Neurochir (Wien). 2001;143:1059-1063.
3. Abou-Hamden A, Koszyca B, Carney PG, et al. Metastasis of renal cell carcinoma to haemangioblastoma of the spinal cord in von Hippel-Lindau disease: case report and review of the literature. Pathology. 2003;35:224-227.
4. Jarrell ST, Vortmeyer AO, Linehan WM, et al. Metastases to hemangioblastomas in von Hippel-Lindau disease. J Neurosurg. 2006;105:256-263.
5. Weinbreck N, Marie B, Bressenot A, et al. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear cell renal cell carcinoma in the brain: utility of aquaporin 1 combined with cytokeratin AE1/AE3 immunostaining. Am J Surg Pathol. 2008;32:1051-1059.
6. Hoang MP, Amirkhan RH. Inhibin alpha distinguishes hemangioblastoma from clear cell renal cell carcinoma. Am J Surg Pathol. 2003;27:1152-1156.
7. Anderson RA, Cambray N, Hartley PS, et al. Expression and localization of inhibin alpha, inhibin/activin betaA and betaB and the activin type II and inhibin beta-glycan receptors in the developing human testis. Reproduction. 2002;123:779-788.
8. Jung SM, Kuo TT. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear renal cell carcinoma. Mod Pathol. 2005;18:788-794.
9. Longatti P, Basaldella L, Orvieto E, et al. Aquaporin 1 expression in cystic hemangioblastomas. Neurosci Lett. 2006;392:178-180.
10. Chen Y, Tachibana O, Oda M, et al. Increased expression of aquaporin 1 in human hemangioblastomas and its correlation with cyst formation. J Neurooncol. 2006;80:219-225.
11. Agre P. The aquaporin water channels. Proc Am Thorac Soc. 2006;3:5-13.
12. Longatti P, Basaldella L, Orvieto E, et al. Choroid plexus and aquaporin-1: A novel explanation of cerebrospinal fluid production. Pediatr Neurosurg. 2004;40:277-283.
13. Weiner HL, Wisoff JH, Rosenberg ME, et al. Craniopharyngiomas: A clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery. 1994;35: 1001-1010.
14. Duff JM, Meyer FB, Ilstrup DM, et al. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery. 2000; 46:291-305.
15. Raghavan R, Dickey WT Jr, Margraf LR, et al. Proliferative activity in craniopharyngiomas: clinicopathological correlations in adults and children. Surg Neurol. 2000;54:241-247.
16. Duo D, Gasverde S, Benech F, et al. MIB-1 immunoreactivity in craniopharyngiomas: A clinicopathological analysis. Clin Neuropathol. 2003;22:229-234.
17. Losa M, Vimercati A, Acerno S, et al. Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma. J Neurol Neurosurg Psychiatry. 2004;75: 889-892.
18. Ikeda H, Yoshimoto T. Clinicopathological study of Rathke's cleft cysts. Clin Neuropathol. 2002;21:82-91.
19. Buslei R, Nolde M, Hofmann B, et al. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumors originating from the sellar region. Acta Neuropathol. 2005;109:589-597.
20. Hofmann BM, Kreutzer J, Saeger W, et al. Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and Rathke cleft cysts: A clinicopathologic approach. Am J Surg Pathol. 2006;30:1595-1603.
21. Wojno KJ, Hruban RH, Garin-Chesa P, et al. Chondroid chordomas and low-grade chondrosarcomas of the craniospinal axis. An immunohistochemical analysis of 17 cases. Am J Surg Pathol. 1992;16:1144-1152.
22. Rosenberg AE, Brown GA, Bhan AK, et al. Chondroid chordoma - a variant of chordoma. A morphologic and immunohistochemical study. Am J Clin Pathol. 1994;101:36-41.
23. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006;209:157-165.
24. Schwab JH, Boland PJ, Agaram NP, et al. Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother. 2009;58:339-349.
25. Showell C, Binder O, Conlon FL. T-box genes in early embryogenesis. Dev Dyn. 2004;229:201-218.
26. Tirabosco R, Nangham DC, Rosenberg AE, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/ myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32:572-580.
27. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma versus chondrosarcoma differential: A tissue microarray-based comparative analysis. Mod Pathol. 2008;21:1461-1469.
28. MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology. 2005;64:1838-1845.
29. Boyd C, Smith MJ, Kluwe L, et al. Alterations in the SMARCB 1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet. 2008;74:358-366.
30. Roberts CW, Orkin SH. The SWI/SNF complex- chromatin and cancer. Nat Rev Cancer. 2004;4:133-142.
31. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009;33:542-550.
32. Kohashi K, Izumi T, Oda Y, et al. Infrequent SMARCB1/ INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol. 2009;40:349-355.
33. Hulsebos TJ, Plomp AS, Wolterman RA, et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet. 2007;80:805-810.
34. Sestini R, Bacci C, Provenzano A, et al. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis- associated schwannomas. Hum Mutat. 2008;29:227-231.
35. Patil S, Perry A, MacCollin M, et al. Immunohistochemical analysis supports a role for INI/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol. 2008;18:517-519.